Antimicrobial Agents and Chemotherapy · 1982 · 45 citations · 4 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial PharmacologyAntimicrobial ResistanceMedical MicrobiologyAntibiotic ResistanceAntimicrobial Susceptibility TestingAntimicrobial TherapyEmpiric Antimicrobial TherapyUrinary Tract Infection PharmacotherapyUrinary Tract InfectionsAntimicrobial Resistance In Urinary Tract InfectionsEscherichia ColiMultidrug-resistant OrganismsNosocomial Urinary Tract InfectionsPseudomonas Aeruginosa ResistanceTetracycline AntibioticsTrimethoprim-sulfamethoxazole TherapyUrinary Tract Infection Antibiotic Therapy
MK-0366, a new derivative of nalidixic acid, was tested against 250 urinary pathogens including Escherichia coli, Serratia marcescens, and Pseudomonas aeruginosa. This new agent was more active than any of the other antibiotics tested, which included carbenicillin, ampicillin, cephalexin, tetracycline, trimethoprim, trimethoprim-sulfamethoxazole, and nalidixic acid. Gentamicin-resistant P. aeruginosa were highly sensitive to MK-0366, with a 90% minimal inhibitory concentration of 0.8 microgram/ml. Serratia strains were the most resistant organisms, with a 90% minimal inhibitory concentration of 3.1 micrograms/ml. These results suggest that clinical trials should be designed to investigate the clinical usefulness of this new drug in urinary infections.
4
In Vitro Antibacterial Activity of AM-715, a New Nalidixic Acid Analog
Akira Itô, Keiji Hirai, Matsuhisa Inoue et al. · Antimicrobial Agents and Chemotherapy · 1980 · 219 citations · Full text